LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Consensus Recommendation of “Moderate Buy” by Analysts

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has earned an average rating of “Moderate Buy” from the six ratings firms that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $68.20.

A number of equities research analysts recently commented on LMAT shares. StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Tuesday. KeyCorp started coverage on LeMaitre Vascular in a research report on Tuesday, February 6th. They set a “sector weight” rating for the company. Finally, Barrington Research raised their target price on LeMaitre Vascular from $66.00 to $69.00 and gave the company an “outperform” rating in a research report on Wednesday, February 28th.

LeMaitre Vascular Trading Down 0.5 %

NASDAQ LMAT opened at $64.12 on Wednesday. The firm has a market capitalization of $1.43 billion, a P/E ratio of 47.85, a PEG ratio of 2.79 and a beta of 0.87. The business has a fifty day simple moving average of $64.88 and a 200 day simple moving average of $57.65. LeMaitre Vascular has a 12 month low of $44.27 and a 12 month high of $74.64.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Tuesday, February 27th. The medical instruments supplier reported $0.38 EPS for the quarter, beating analysts’ consensus estimates of $0.36 by $0.02. The business had revenue of $48.90 million during the quarter, compared to analyst estimates of $49.01 million. LeMaitre Vascular had a return on equity of 10.57% and a net margin of 15.56%. LeMaitre Vascular’s quarterly revenue was up 19.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.25 EPS. As a group, sell-side analysts predict that LeMaitre Vascular will post 1.66 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Thursday, March 14th were issued a $0.16 dividend. The ex-dividend date of this dividend was Wednesday, March 13th. This represents a $0.64 annualized dividend and a yield of 1.00%. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.14. LeMaitre Vascular’s dividend payout ratio (DPR) is 47.76%.

Insider Buying and Selling

In related news, Director Lawrence J. Jasinski sold 5,110 shares of LeMaitre Vascular stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total value of $344,925.00. Following the completion of the sale, the director now owns 5,309 shares of the company’s stock, valued at approximately $358,357.50. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other LeMaitre Vascular news, CEO George W. Lemaitre sold 36,600 shares of the firm’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $68.03, for a total value of $2,489,898.00. Following the completion of the transaction, the chief executive officer now owns 2,187,526 shares in the company, valued at approximately $148,817,393.78. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Lawrence J. Jasinski sold 5,110 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total value of $344,925.00. Following the completion of the transaction, the director now owns 5,309 shares of the company’s stock, valued at approximately $358,357.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 114,036 shares of company stock valued at $7,873,749. 12.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Exchange Traded Concepts LLC boosted its stake in LeMaitre Vascular by 0.8% in the 4th quarter. Exchange Traded Concepts LLC now owns 23,656 shares of the medical instruments supplier’s stock worth $1,343,000 after purchasing an additional 187 shares during the period. Riverwater Partners LLC boosted its position in shares of LeMaitre Vascular by 2.5% during the 4th quarter. Riverwater Partners LLC now owns 8,216 shares of the medical instruments supplier’s stock valued at $466,000 after acquiring an additional 198 shares during the last quarter. Legal & General Group Plc boosted its position in shares of LeMaitre Vascular by 0.4% during the 2nd quarter. Legal & General Group Plc now owns 45,769 shares of the medical instruments supplier’s stock valued at $2,084,000 after acquiring an additional 200 shares during the last quarter. Cerity Partners LLC bought a new stake in shares of LeMaitre Vascular during the 1st quarter valued at about $380,000. Finally, Sei Investments Co. boosted its position in shares of LeMaitre Vascular by 0.8% during the 4th quarter. Sei Investments Co. now owns 30,471 shares of the medical instruments supplier’s stock valued at $1,402,000 after acquiring an additional 248 shares during the last quarter. Institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.